Sugi Predict

Sugi Predict / Targets / PARG

PARG

Poly(ADP-ribose) glycohydrolase · Q86W56 · PARG on Sugi Atlas →

16,372 patent compounds predicted against PARG, 7,575 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2595040 SCHEMBL2595040 0.53 17/20
SCHEMBL653027 SCHEMBL653027 0.43 11/20
SCHEMBL60256 SCHEMBL60256 0.72 7/20
SCHEMBL2459264 SCHEMBL2459264 0.62 7/20
Potassium Ion Potassium Ion (SCHEMBL2784885) 0.59 7/20
SCHEMBL2858677 SCHEMBL2858677 0.59 7/20
Water Water (SCHEMBL1976332) 0.57 7/20
SCHEMBL919135 SCHEMBL919135 0.54 7/20
SCHEMBL626766 SCHEMBL626766 0.54 7/20
SCHEMBL2167466 SCHEMBL2167466 0.53 7/20
Water Water (SCHEMBL2154885) 0.53 7/20
Water Water (SCHEMBL1976333) 0.51 7/20
Potassium Ion Potassium Ion (SCHEMBL2077835) 0.50 7/20
SCHEMBL3821330 SCHEMBL3821330 0.50 7/20
SCHEMBL1615844 SCHEMBL1615844 0.88 6/20
SCHEMBL918573 SCHEMBL918573 0.61 6/20
SCHEMBL305527 SCHEMBL305527 0.59 6/20
SCHEMBL2517727 SCHEMBL2517727 0.41 6/20
SCHEMBL2388342 SCHEMBL2388342 0.38 6/20
SCHEMBL426122 SCHEMBL426122 0.54 5/20

Clinical trials — most relevant to PARG by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies PHASE1/PHASE2RECRUITING
Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor PHASE2COMPLETED
Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients PHASE2UNKNOWN
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment PHASE2ACTIVE_NOT_RECRUITING
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer PHASE2ACTIVE_NOT_RECRUITING
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) PHASE2RECRUITING
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) PHASE1/PHASE2COMPLETED
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer PHASE2ACTIVE_NOT_RECRUITING
Phase II ABT-888 With Cyclophosphamide PHASE2COMPLETED
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma PHASE1ACTIVE_NOT_RECRUITING
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer PHASE1UNKNOWN
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction PHASE1ACTIVE_NOT_RECRUITING
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer PHASE1COMPLETED
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway PHASE1NOT_YET_RECRUITING
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer PHASE1ACTIVE_NOT_RECRUITING
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers PHASE1COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors PHASE1COMPLETED
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts PHASE1ACTIVE_NOT_RECRUITING
Study of AMG 650 in Adult Participants With Advanced Solid Tumors PHASE1COMPLETED
PET Imaging of PARP Activity in Cancer EARLY_PHASE1UNKNOWN
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer nanNO_LONGER_AVAILABLE
PPK Study Based on Quantitative Pharmacology in Patients With Pamipril nanUNKNOWN
Efficacy and Adverse Effects of Olaparib in Ovarian Cancer. nanUNKNOWN
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PARG binder may also engage these)

ProteinNameSimilarity
O88622 — 1.000 O88622 →
Q9QYM2 — 1.000 Q9QYM2 →
O02776 — 0.999 O02776 →
Q6A037 — 0.988 Q6A037 →
Q8BMI4 — 0.988 Q8BMI4 →
Q4G0A6 — 0.987 Q4G0A6 →
Q5QJC2 — 0.987 Q5QJC2 →
P62287 — 0.987 P62287 →
Q5TKR9 — 0.987 Q5TKR9 →
Q2KIP2 — 0.987 Q2KIP2 →
Q5ZLE9 — 0.987 Q5ZLE9 →
Q5QJC4 — 0.987 Q5QJC4 →
Q08D35 — 0.987 Q08D35 →
P62292 — 0.987 P62292 →
P14629 — 0.987 P14629 →
TOR1AIP1 Torsin-1A-interacting protein 1 0.987 landscape →
Q5PQX1 — 0.987 Q5PQX1 →
Q92613 — 0.986 Q92613 →
Q80Y19 — 0.986 Q80Y19 →
P62291 — 0.986 P62291 →
Q07G43 — 0.986 Q07G43 →
P62297 — 0.986 P62297 →
DCLRE1A DNA cross-link repair 1A protein 0.986 landscape →
Q6GNV6 — 0.986 Q6GNV6 →
O75113 — 0.986 O75113 →
Q3UQI9 — 0.986 Q3UQI9 →
Q5T5J6 — 0.986 Q5T5J6 →
Q9JIC3 — 0.986 Q9JIC3 →
P62289 — 0.986 P62289 →
P62290 — 0.986 P62290 →